Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million.
週二，Esperion Therapeutics（納斯達克股票代碼：ESPR）公佈的第一季度收入爲1.374億美元，同比增長467％，超過了市場預期的8451萬美元。
The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05.
該公司公佈的每股收益爲0.34美元，較去年同期的每股虧損0.79美元（0.79美元）有所扭轉，超過了市場預期的0.05美元。
U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growth within partner territories along with the settlement-related milestone payment.
美國淨產品收入爲2480萬美元，同比增長約46％。協作收入爲1.13億美元，而去年同期爲730萬美元，這得益於對國際合作夥伴的平板電腦銷售增加以及合作伙伴區域內的銷售增長以及與和解相關的里程碑付款。
"We posted retail prescription equivalent growth of 43% year-over-year, generated our highest level of revenue yet, and ended the quarter with a cash balance that positions us to capitalize on our new label and deliver long-term value growth," said Sheldon Koenig, President and CEO.
總裁兼首席執行官謝爾登·科尼格表示：“我們公佈的零售處方等價物同比增長了43％，創造了迄今爲止最高的收入水平，並在本季度末實現了現金餘額，使我們能夠利用新標籤並實現長期價值增長。”
In March, the FDA approved broad new label expansions for Esperion Therapeutics' NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in primary and secondary prevention patients.
3月，美國食品藥品管理局根據CLEAR結果數據，批准了Esperion Therapeutics的NEXLETOL（本培多酸）片劑和NEXLIZET（本培多酸和依澤替米貝）片劑的廣泛新標籤擴展，其中包括降低初級和二級預防患者的心血管風險和擴大降低低密度脂蛋白的適應症。
During the quarter, the company initiated new commercial initiatives to increase patient awareness of NEXLETOL and NEXLIZET's expanded labels. Expanded sales force to 150 representatives in the U.S. and developed new promotional materials and tools to supplement salesforce efforts.
在本季度，該公司啓動了新的商業舉措，以提高患者對NEXLETOL和NEXLIZET擴展標籤的認識。將銷售隊伍擴大到美國的150名代表，並開發了新的宣傳材料和工具以補充銷售隊伍的工作。
The company initiated the technology transfer process for NILEMDO and NUSTENDI tablet manufacturing to Daiichi Sankyo Europe for its territories, which is expected to be completed in the second half of 2025.
該公司啓動了向第一三共歐洲公司在其領土上生產NILEMDO和NUSTENDI平板電腦的技術轉讓程序，該過程預計將於2025年下半年完成。
Additionally, as part of the amended partnership, the company authorized Daiichi Sankyo Europe to proceed with commercialization of a triple formulation product comprising bempedoic acid, ezetimibe, and a statin, which, if approved, has the potential to extend the product's lifecycle in Europe.
此外，作爲修訂後的合作伙伴關係的一部分，該公司授權第一三共歐洲公司着手將一種包含本培多酸、依折替米貝和他汀類藥物的三聯配方產品的商業化，如果獲得批准，有可能延長該產品在歐洲的生命週期。
Guidance: Esperion Therapeutics expects fiscal year 2024 operating expenses of $225 million-$245 million.
指導方針：Esperion Therapeutics預計，2024財年的運營支出爲2.25億至2.45億美元。
Price Action: ESPR shares are up 5.20% at $2.23 at last check Tuesday.
價格走勢：週二最後一次檢查時，ESPR股價上漲5.20％，至2.23美元。
譯文內容由第三人軟體翻譯。